Ceftolozane
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ceftolozane: Ureaplasma urethritis
One-Sentence Summary
Ceftolozane is a cephalosporin antibiotic originally used to treat urinary tract infection. The TxGNN model predicts it may be effective for Ureaplasma urethritis with a very high score, but no clinical trials and no publications currently support this prediction. The biological rationale is also weak, so this is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Ureaplasma urethritis |
| TxGNN Prediction Score | 0.9989 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, ceftolozane is a beta-lactam cephalosporin that inhibits bacterial penicillin-binding proteins (PBPs). It is optimised for activity against Pseudomonas aeruginosa and Enterobacterales, which is why it is used for urinary tract infection.
For the top predicted indication, the mechanistic link is weak. Ureaplasma species have no cell wall, so beta-lactam antibiotics are expected to be intrinsically ineffective against them. The high TxGNN score most likely reflects the model grouping drugs by the shared category of urogenital infection, rather than a real biological effect.
Other predictions fit better. The best-supported one is xanthogranulomatous pyelonephritis (score 0.9988), a chronic renal infection often caused by Gram-negative bacteria such as Proteus and E. coli. It is closely related to the existing urinary infection use. However, definitive treatment is usually surgical, and the available literature is only an indirect general review.
Other notable predictions:
- Gonococcal urethritis (0.9989): some cephalosporins, such as ceftriaxone, work against Neisseria gonorrhoeae, so a class-level rationale exists. Ceftolozane itself has no clinical or literature data for this use.
- Uterine inflammatory disease (0.9988): pelvic infections are often polymicrobial, and ceftolozane/tazobactam has Gram-negative activity. The rationale is plausible but unsupported.
- Urogenital tuberculosis (0.9950): M. tuberculosis has a native beta-lactamase and low beta-lactam susceptibility, so this is unlikely.
- Non-infectious conditions (hyperviscosity syndrome, hyperamylasemia, congenital analbuminemia, blood group incompatibility, premalignant haematological disease): no antibacterial target exists, and these scores are likely artifacts.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
For the top predicted indication, Ureaplasma urethritis, currently no related literature is available. The only publication found relates to the fourth-ranked prediction, xanthogranulomatous pyelonephritis:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26658652 | 2016 | Review | Current Opinion in Infectious Diseases | Review of insights on complicated febrile urinary tract infections, including pyelonephritis and urosepsis. It is indirect evidence and does not study ceftolozane. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02446901 | ZERBAXA | Not listed | Not listed |
Safety Considerations
Drug Interactions: 11 interactions were identified, all rated Moderate:
- Aminoglycosides: kanamycin, neomycin, streptomycin, amikacin (including liposomal), gentamicin
- Anticoagulants: warfarin, dicoumarol
- Others: chloramphenicol, ethinylestradiol, mycophenolic acid
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction is supported only by the model score (L5), with no trials or literature. The biology also argues against it, because Ureaplasma lacks a cell wall and beta-lactams are not expected to work. The same applies to most other high-scoring predictions. Xanthogranulomatous pyelonephritis is the only one worth keeping as a research question, and even there the evidence is indirect.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data
- In vitro susceptibility data for ceftolozane against the target organisms (Ureaplasma, N. gonorrhoeae, and uropathogens linked to xanthogranulomatous pyelonephritis)
- A focused literature search on ceftolozane/tazobactam in pyelonephritis and pelvic infection
- Approved indication text for the Canadian licence, to confirm the original indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.